We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Close Menu
Contact

Browsing: ctcl

Health

Kyowa Kirin reveals new CTCL study findings at EORTC meeting

By 0

Kyowa Kirin International (KKI) has announced the upcoming presentation of interim findings from three significant real-world studies focusing on cutaneous T-cell lymphoma (CTCL) at the European Organisation for Research and Treatment of Cancer’s Cutaneous Lymphoma Tumour Group (EORTC-CLTG) annual meeting. The event is set to take place in Lausanne, Switzerland, from 9 to 11 October 2024. These studies involve participants from Europe, the United States, and the United Arab Emirates, and aim to gather evidence regarding the effectiveness of mogamulizumab, a pioneering humanised monoclonal antibody therapy. This treatment is currently approved in Europe and the UAE for adult patients with…

Read More

Tamar Bridge News is your trusted guide through the currents of UK news, committed to bridging the gap between information and insight with clarity, precision, and a human-centric approach.

Company

Latest Stories

© 2025 Tamar Bridge News | All rights reserved